Posttranslational modifications of PD-L1 and their applications in cancer therapy

Jung Mao Hsu, Chia Wei Li, Yun Ju Lai, Mien Chie Hung

Research output: Contribution to journalArticlepeer-review

168 Scopus citations

Abstract

Posttranslational modifications (PTM) of PD-L1 have emerged as important regulatory mechanisms that modulate immunosuppression in patients with cancer. In exposure to inflammatory cytokines, cancer cells and antigen-presenting cells, such as macrophages and dendritic cells, express PD-L1 to inhibit the activity of effector T cells through PD-1 engagement. Recent studies suggested that glycosylation, phosphorylation, ubiquitination, sumoylation, and acetylation play important roles in the regulation of PD-L1 protein stability and translocation and protein–protein interactions. Aberrant alterations of PTMs directly influence PD-L1–mediated immune resistance. On the basis of the newly identified regulatory signaling pathways of PD-L1 PTMs, researchers have investigated the cancer therapeutic potential of natural food compounds, small-molecule inhibitors, and mAbs by targeting PD-L1 PTMs. Results of these preclinical studies demonstrated that targeting PTMs of PD-L1 yields promisin antitumor effects and that clinical translation of these therapeutic strategies is warranted.

Original languageEnglish (US)
Pages (from-to)6349-6353
Number of pages5
JournalCancer Research
Volume78
Issue number22
DOIs
StatePublished - Nov 15 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Posttranslational modifications of PD-L1 and their applications in cancer therapy'. Together they form a unique fingerprint.

Cite this